Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Conference Call November 20, 2023 4:30 PM ET

Company Participants

Jennifer Viera - Investor Relations

Jay Luly - President and Chief Executive Officer

Paul Mellett - Chief Financial Officer

Scott Rottinghaus - Chief Medical Officer

Conference Call Participants

Roanna Ruiz - Leerink Partners

Jay Olson - Oppenheimer

Ed Arce - H.C. Wainwright & Company

Eric Joseph - JPMorgan

Liisa Bayko - Evercore

Roy Buchanan - JMP

Operator

Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded.

I would now like to turn the conference to your host Ms. Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon.

The news release with our fiscal fourth quarter and year-end 2023 financial results was issued this afternoon and is available on our website.

Making formal remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Senior Vice President of New Product Strategy and Development, will be available during the Q&A portion of the call.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-K and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during the call.

With that, I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone.

In fiscal 2023, Enanta took important steps leading to meaningful progress in addressing the unmet need for treating serious respiratory viruses and advancing our business objectives. As we look toward the future, we continue to assess opportunities that will leverage our expertise to transform the lives of patients by discovering novel treatments for viral infections and other diseases. 2024 is shaping up to be an important year for us with multiple inflection points expected, including potential growth into new therapeutic areas.